10/3/03

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)	Attorney Docket Number 8789-49CT	Serial No. ~~To Be Assigned~~
	Applicants: Leonard.	
	Filing Date Concurrently Herewith	1614 Group ~~To Be Assigned~~

U. S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1.	RE 36,247	07/1999	Plunkett et al.			
	2.	5,891,867	04/1999	Lanquetin et al.			
	3.	5,827,843	10/1998	Koninckx			
	4.	5,208,225	05/1993	Boissonneault et al.			
	5.	5,108,995	04/1992	Casper			
	6.	5,043,331	08/1991	Hirvonen et al.			
	7.	5108995	4/1992	Casper			
	8.	5,935,949	8/1999	White			
	9.	4,425,339	01/1984	Pitchford			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes | No
	10.	WO 98/06404	2/1998	WIPO			
	11.	WO 00/74684	12/2000	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	12.	Simon et al., *Unscheduled Bleeding During Initiation of Continuous Combined Hormone Replacement Therapy: A Direct Comparison of Two Combinations of Norethindrone Acetate and Ethinyl Estradiol to Medroxyprogesterone Acetate and Conjugated Equine Estrogens*, Menopause, The Journal of the North American Menopause Society, Vol. 8, No. 5, 2001, pp. 321-327
	13.	Pickar et al., *Endometrial Effects of Lower Doses of Conjugated Equine Estrogens and Medroxyprogesterone Acetate*, Fertility and Sterility, Vol. 76, No. 1, July 2001, pp. 25-31
	14.	Chesnut et al., *A Randomized Trial of Nasal Spray Salmon Calcitonin in Postmenopausal Women With Established Osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study*, The American Journal of Medicine, Vol. 109, September 2000, pp. 267-276
	15.	Archer et al., *Effects of Lower Doses of Conjugated Equine Estrogens and Medroxyprogesterone Acetate On Endometrial Bleeding*, Fertility and Sterility, Vol. 75, No. 6, June 2001, pp. 1080-1087
	16.	Dawson et al., *A Randomized Study Comparing Standard Versus Moderately High Dose Megestrol Acetate for Patients With Advanced Prostate Carcinoma*, Cancer, Vol. 88, No. 4, February 15, 2000 (cont)

EXAMINER [signature] DATE CONSIDERED 7/10/07

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

10/3/03

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)	Attorney Docket Number 8789-49CT	Serial No. To Be Assigned
	Applicants: Leonard.	
	Filing Date Concurrently Herewith	Group To Be Assigned

		142, No. 6, March 15, 1982, pp. 791-795
	35.	*Megestrol Acetate*, IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Vol. 21, 1979, pp. 431-439
	36.	Donkervoort et al., *Megestrol Acetate in Treatment of Benign Prostatic Hypertrophy*, Urology, Vol. VI, No. 5, November 1975, pp. 580-587
	37.	Tisell et al., *Androgenic Properties and Adrenal Depressant Activity of Megestrol Acetate Observed in Castrated Male Rats*, Acta Endocrinologica, Vol. 78, 1975, pp. 316-324
	38.	Burke et al., *Megestrol Acetate for Estrus Postponement in the Bitch*, JAVMA, Vol. 167, No. 4, pp. 285-287 (Date NOT Available).
	39.	Wait, *Megestrol Acetate in the Management of Advanced Endometrial Carcinoma*, Obstetrics and Gynecology, Vol. 41, No. 1, January 1973, pp. 129-136
	40.	Balin et al., *Low Dosage Megestrol Acetate Application as Contraceptive*, The Journal of Reproductive Medicine, Vol. V, No. 1, July 1979, pp. 74-81
	41.	Cooper et al., *The Metabolism of Megestrol Acetate (17 ∀-Acetoxy-6-Methylpregna-4,6-Diene-3,20-Dione) in Women*, Steroids, Vol. 11, No. 2, February 1968, pp. 133-149
	42.	International Search Report corresponding to PCT/US 02/15690 mailed on May 12, 2002.
	43.	O'Connor, Vivenne M. "Managing Menopause: Part 2: what are the choices in treatment?" MedicineToday pgs. 30-40 February (2001).
	44.	David et al., *Anti-Ovulatory and Other Biological Properties of Megestrol Acetate 17 ∀-Acetoxy-6 Methyl Pregna 4:6-Diene-3:20-Dione (B.D.H. 1298)*, J. Reprod. Fertil., Vol. 5, 1963, pp. 331-346

EXAMINER [signature] DATE CONSIDERED 7/10/07

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

10/3/03

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)	Attorney Docket Number 8789-49CT	Serial No. ~~To Be Assigned~~
	Applicants: Leonard.	
	Filing Date Concurrently Herewith	Group 1614 ~~To Be Assigned~~

		pp. 825-834
	17.	Farinha et al., *Improved Bioavailability of a Micronized Megestrol Acetate Tablet Formulation in Humans*, Drug Development and Industrial Pharmacy, Vol. 26, No. 5, 2000, pp. 567-570
	18.	Naing et al., *Megestrol Acetate Therapy and Secondary Adrenal Suppression*, Cancer, Vol. 86, No. 6, September 15, 1999, pp. 1044-1049
	19.	Bernhard et al., *Quality of Life in Postmenopausal Patients With Breast Cancer After Failure of Tamoxifen: Formestane Versus Megestrol Acetate as Second-Line Hormonal Treatment*, European Journal of Cancer, Vol. 35, No. 6, 1999, pp. 913-920
	20.	Loprinzi et al., *Randomized Comparison of Megestrol Acetate Versus Dexamethasone Versus Fluoxymesterone for the Treatment of Cancer Anorexia/Cachexia*, Journal of Clinical Oncology, Vol. 17, No. 10, October 1999, pp. 3299-3306
	21.	Engelson et al., *Effects of Megestrol Acetate and Testosterone on Body Composition in Castrated Male Sprague-Dawley Rats*, Nutrition, Vol. 15, No. 6, 1999, pp. 465-473
	22.	Critchley et al., *Effects of Estrogen and Progesterone on the Endometrium*, Estrogens and Progestagens in Clinical Practice, edited by Fraser et al., 1998, pp. 145-161
	23.	Ross et al., *Endometrial Effects of Three Doses of Trimegestone a New Orally Active Progestogen, On the Postmenopausal Endometrium*, Maturitas, Vol. 28, 1997, pp. 83-88
	24.	Conard et al., *Cardiovascular Risk Factors and Combined Estrogen-Progestin Replacement Therapy: A Placebo-Controlled Study With Nomegestrol Acetate and Estradiol*, Fertility and Sterility, Vol. 64, No. 5, November 1995, pp. 957-962
	25.	Sturdee et al., *Is the Timing of Withdrawal Bleeding a Guide to Endometrial Safety During Sequential Oestrogen-Progestagen Replacement Therapy?*, The Lancet, Vol. 334, October 8, 1994, pp. 979-982
	26.	Von Roenn, *Randomized Trials of Megestrol Acetate for AIDS-Associated Anorexia and Cachexia*, Oncology, Vol. 51, Suppl 1, 1994, pp. 19-24
	27.	Espie, *Megestrol Acetate in Advanced Breast Carcinoma*, Oncology, Vol. 51, Suppl 1, 1994, pp. 8-12
	28.	Loprinzi et al., *Megestrol Acetate for the Prevention of Hot Flashes*, The New England Journal of Medicine, Vol. 331, No. 6, August 11, 1994, pp. 347-352
	29.	Sporrong et al., *A Novel Statistical Approach to Analysis of Bleeding Patterns During Continuous Hormone Replacement Therapy*, Maturitas, Vol. 11, 1989, pp. 209-215
	30.	Schacter et al., *Megestrol Acetate: Clinical Experience*, Cancer Treatment Reviews, Vol. 16, 1989, pp. 49-63
	31.	Sporrong et al., *Comparison of Four Continuously Administered Progestogen Plus Oestradiol Combinations for Climacteric Complaints*, British Journal of Obstetrics and Gynaecology, Vol. 95, October 1988, pp. 1042-1048
	32.	Alexieva-Figusch et al., *Treatment of Metastatic Breast Cancer Patients With Different Dosages of Megestrol Acetate; Dose Relations, Metabolic and Endocrine Effects*, Eur J Cancer Clin Oncol, 1984, pp. 33-40
	33.	Canetta et al., *Megestrol Acetate*, Cancer Treatment Reviews, Vol. 10, 1983, pp. 141-157
	34.	Whitehead et al., *Actions of Progestins on the Morphology and Biochemistry of the Endometrium of Postmenopausal Women Receiving Low-Dose Estrogen Therapy*, Am M Obstet Gynecol Vol

(Postmenopausal Women Receiving Low Dose Estrogen Therapy Am M Obstet. Gynecol. Vol. (cont)-7

EXAMINER _____ DATE CONSIDERED 7/10/07

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.